Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Montine, Thomas J ^a   Sonnen, Joshua A ^a   Milne, Ginger ^c   Baker, Laura D ^b   Breitner, John C S ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; CELECOXIB; ISOPROSTANE DERIVATIVE; NAPROXEN; PROSTACYCLIN; THROMBOXANE; 11 DEHYDRO THROMBOXANE B2; 11-DEHYDRO-THROMBOXANE B2; 6 OXOPROSTAGLANDIN F1 ALPHA; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE; THROMBOXANE B2;

ADVERSE OUTCOME; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; FEMALE; HUMAN; IN VIVO STUDY; ISOTOPE DILUTION ASSAY; KIDNEY CONCENTRATING CAPACITY; MALE; MASS FRAGMENTOGRAPHY; METABOLITE; SELF REPORT; URINE; ALZHEIMER DISEASE; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

6-KETOPROSTAGLANDIN F1 ALPHA; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; F2-ISOPROSTANES; FEMALE; HUMANS; MALE; NAPROXEN; PYRAZOLES; SULFONAMIDES; THROMBOXANE B2; TREATMENT OUTCOME;

EID: 77949502713     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009340     Document Type: Article

References (17)

1. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, et al. (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117: 2104-2113.
2. Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4-15.
3. Bresalier RS, Friedewald VE, Jr., Rakel RE, Roberts WC, Williams GW (2005) The Editor's roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk. Am J Cardiol 96: 1589-1604.
4. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, et al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081-1091.
5. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080.
6. Furberg CD, Psaty BM, FitzGerald GA (2005) Parecoxib, valdecoxib, and cardiovascular risk. Circulation 111: 249.
7. Penglis PS, Cleland LG, Demasi M, Caughey GE, James MJ (2000) Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J Immunol 165: 1605-1611.
8. Brock TG, McNish RW, Peters-Golden M (1999) Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem 274: 11660-11666.
9. McAdam BF, Byrne D, Morrow JD, Oates JA (2005) Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation 112: 1024-1029.
10. Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ (2001) Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 167: 2831-2838.
11. Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, et al. (2004) Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23: 159-169.
12. Szekely CA, Breitner JC, Zandi PP (2007) Prevention of Alzheimer's disease. Int Rev Psychiatry 19: 693-706.
13. (2006) Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 1: e33.
14. 2a. J Biol Chem 270: 9800-9808.
15. 2a in vitro and in vivo via the cyclooxygenases. J Pharmacol Exp Ther 282: 1658-1665.
16. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, et al. (1995) Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 332: 1198-1203.
17. 4 poisoning. Free Radic Biol Med 38: 711-718.